Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • GASTROINTESTINAL CANCER  (1)
  • 1
    Keywords: CANCER ; SURVIVAL ; tumor ; COMBINATION ; Germany ; PHASE-I ; THERAPY ; TOXICITY ; DEATH ; DISEASE ; RISK ; TUMORS ; TIME ; PATIENT ; RESPONSES ; 5-FLUOROURACIL ; ACID ; TRIAL ; PROGRESSION ; AGE ; chemotherapy ; doxorubicin ; SAFETY ; FLUOROURACIL ; CISPLATIN ; GASTRIC-CANCER ; BOLUS ; PHASE-II ; SINGLE ; ELDERLY-PATIENTS ; SODIUM ; gastric cancer ; INTERVAL ; PHASE ; TOLERABILITY ; PLUS ; EUROPEAN-ORGANIZATION ; NAUSEA ; COOPERATIVE GROUP ; EPIRUBICIN ; GASTROINTESTINAL CANCER ; HIGH-DOSE METHOTREXATE ; mitomycin C ; pegylated liposomal ; phase II ; SUPPORTIVE CARE ; LIPOSOMAL DOXORUBICIN
    Abstract: Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors. In the present study, we investigated activity and tolerability of this three-drug regimen in patients with gastric cancer. Patients with advanced or metastatic gastric cancer were recruited to receive weekly infusional 5-FU (2000 mg/m(2)) mixed with sodium folinic acid (FA; 500 mg/m(2)) in one pump (days 1, 8,15, 22, 29, 36). On days 1 and 29, Caelyx (20 mg/m(2)) was given as a 1-h, and MMC (7 mg/m(2)) was applied as bolus injection on days 8 and 36. Treatment courses were repeated on day 57. Twenty-seven patients with a median age of 66 years were recruited in a single center; 56% had histologically proven peritoneal carcinomatosis and 26 patients are evaluable for toxicity. Common Toxicity Criteria of the National Cancer Institute grade 3 toxicity was recorded in 34% of the patients (anemia 12%, leukocytopenia 8%, febrile neutropenia 4%, thrombocytopenia 12%, nausea 15%, diarrhea 8% and mucositis 4%). One patient developed hemolytic-uremic syndrome. One complete (5%) and eight partial responses (42%) were observed in 19 patients evaluable for response according to WHO criteria. Seven patients had no change (37%) and three (16%) progressive disease. Six patients with peritoneal carcinomatosis not amenable to WHO response assessment had progression-free intervals between 8 and 21 months. Median survival for all patients was 14.7 months and median time to progression was 8.4 months. We conclude that this new three-drug combination regimen yields a promising overall response rate (47%) in patients with gastric cancer despite the inclusion of a majority of elderly patients at moderate or high risk of death in this trial. Its safety and good tolerability as established in the phase I trial was confirmed. (c) 2005 Lippincott Williams M Wilkins
    Type of Publication: Journal article published
    PubMed ID: 15746580
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...